Evidence map›Paper›PMID 39139547›Full record

ArticleOphthalmology science

An in vitro 3-dimensional Collagen-based Corneal Construct with Innervation Using Human Corneal Cell Lines.

Mohammad Mirazul Islam, Amrita Saha, Farzana Afrose Trisha, Miguel Gonzalez-Andrades, Hirak K Patra, May Griffith, James Chodosh, Jaya Rajaiya

Abstract read
In one paragraph

Article in Ophthalmology science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mohammad Mirazul IslamDepartment of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear and Schepens Eye Research Institute, Boston, Massachusetts.
Amrita SahaDepartment of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear and Schepens Eye Research Institute, Boston, Massachusetts.
Farzana Afrose TrishaDepartment of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear and Schepens Eye Research Institute, Boston, Massachusetts.
Miguel Gonzalez-AndradesDepartment of Ophthalmology, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital and University of Cordoba, Cordoba, Spain.
Hirak K PatraUCL Division of Surgery and Interventional Science, Department of Surgical Biotechnology, University College London, London, UK.
May GriffithDepartment of Ophthalmology, Université de Montréal and Centre de recherche de l'Hôpital Maisonneuve Rosemont, Montreal, Quebec, Canada.
James ChodoshDepartment of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear and Schepens Eye Research Institute, Boston, Massachusetts.
Jaya RajaiyaDepartment of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear and Schepens Eye Research Institute, Boston, Massachusetts.

Funding

VISION RESEARCHP30EY003790 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Patricia Ann D'Amore · 1985 to 2026
$25.5M
Immunopathogenesis of Adenovirus KeratitisR01EY013124 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI James Chodosh, Jaya Rajaiya · 2001 to 2026
$10.8M
Novel Mechanisms in Adenoviral Ocular PathogenesisR01EY021558 · NEI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI James Chodosh, Jaya Rajaiya · 2011 to 2026
$7.1M
Mesenchymal Stem Cells can Restore and Maintain Corneal Endothelial FunctionR00EY031373 · NEI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Mohammad Mirazul Islam · 2024 to 2026
$746k
Mesenchymal Stem Cells can Restore and Maintain Corneal Endothelial FunctionK99EY031373 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI ISLAM, MOHAMMAD MIRAZUL · 2021 to 2022
$213k
NEI NIH HHS K99 EY031373NEI NIH HHS P30 EY003790NEI NIH HHS R00 EY031373NEI NIH HHS R01 EY013124NEI NIH HHS R01 EY021558
6 · The paper itself

Abstract

Purpose: To develop a 3-dimensional corneal construct suitable for in vitro studies of disease conditions and therapies. Design: In vitro human corneal constructs were created using chemically crosslinked collagen and chondroitin sulfate extracellular matrix and seeded with 3 human corneal cell types (epithelial, stromal, and endothelial) together with neural cells. The neural cells were derived from hybrid neuroblastoma cells and the other cells used from immortalized human corneal cell lines. To check the feasibility and characterize the constructs, cytotoxicity, cell proliferation, histology, and protein expression studies were performed. Results: Optimized culture condition permitted synchronized viability across the cell types within the construct. The construct showed a typical appearance for different cellular layers, including healthy appearing, phenotypically differentiated neurons. The expected protein expression profiles for specific cell types within the construct were confirmed with western blotting. Conclusions: An in vitro corneal construct was successfully developed with maintenance of individual cell phenotypes with anatomically correct cellular loci. The construct may be useful in evaluation of specific corneal disorders and in developing different corneal disease models. Additionally, the construct can be used in evaluating drug targeting and/or penetration to individual corneal layers, testing novel therapeutics for corneal diseases, and potentially reducing the necessity for animals in corneal research at the early stages of investigation. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Indexed as

Corneal extracellular matrixCrosslinkingDisease modelIn vitro 3D corneal construct

Identifiers

PMID39139547
PMCPMC11321308

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.